Literature DB >> 15828019

Polyamine depletion inhibits NF-kappaB binding to DNA and interleukin-8 production in human chondrocytes stimulated by tumor necrosis factor-alpha.

Annalisa Facchini1, Rosa Maria Borzí, Kenneth B Marcu, Claudio Stefanelli, Eleonora Olivotto, Mary B Goldring, Andrea Facchini, Flavio Flamigni.   

Abstract

The activation of the NF-kappaB pathway by pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNFalpha), can be an important contributor for the re-programming of chondrocyte gene expression, thereby making it a therapeutic target in articular diseases. To search for new approaches to limit cartilage damage, we investigated the requirement of polyamines for NF-kappaB activation by TNFalpha in human C-28/I2 chondrocytes, using alpha-difluoromethylornithine (DFMO), a specific polyamine biosynthesis inhibitor. The NF-kappaB pathway was dissected by using pharmacological inhibitors or by expressing a transdominant IkappaBalpha super repressor. Treatment of C-28/I2 chondrocytes with TNFalpha resulted in a rapid enhancement of nuclear localization and DNA binding activity of the p65 NF-kappaB subunit. TNFalpha also increased the level and extracellular release of interleukin-8 (IL-8), a CXC chemokine that can have a role in arthritis, in an NF-kappaB-dependent manner. Pre-treatment of chondrocytes with DFMO, while causing polyamine depletion, significantly reduced NF-kappaB DNA binding activity. Moreover, DFMO also decreased IL-8 production without affecting cellular viability. Restoration of polyamine levels by the co-addition of putrescine circumvented the inhibitory effects of DFMO. Our results show that the intracellular depletion of polyamines inhibits the response of chondrocytes to TNFalpha by interfering with the DNA binding activity of NF-kappaB. This suggests that a pharmacological and/or genetic approach to deplete the polyamine pool in chondrocytes may represent a useful way to reduce NF-kappaB activation by inflammatory cytokines in arthritis without provoking chondrocyte apoptosis. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15828019      PMCID: PMC1226412          DOI: 10.1002/jcp.20368

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  47 in total

1.  Flow cytometric analysis of intracellular chemokines in chondrocytes in vivo: constitutive expression and enhancement in osteoarthritis and rheumatoid arthritis.

Authors:  R M Borzi; I Mazzetti; S Macor; T Silvestri; A Bassi; L Cattini; A Facchini
Journal:  FEBS Lett       Date:  1999-07-23       Impact factor: 4.124

Review 2.  Signal transduction and transcription factors in rheumatic disease.

Authors:  G S Firestein; A M Manning
Journal:  Arthritis Rheum       Date:  1999-04

3.  Characterization and quantitation of NF-kappaB nuclear translocation induced by interleukin-1 and tumor necrosis factor-alpha. Development and use of a high capacity fluorescence cytometric system.

Authors:  G J Ding; P A Fischer; R C Boltz; J A Schmidt; J J Colaianne; A Gough; R A Rubin; D K Miller
Journal:  J Biol Chem       Date:  1998-10-30       Impact factor: 5.157

Review 4.  The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models.

Authors:  M B Goldring
Journal:  Connect Tissue Res       Date:  1999       Impact factor: 3.417

5.  p44/42 mitogen-activated protein kinase is involved in the expression of ornithine decarboxylase in leukaemia L1210 cells.

Authors:  F Flamigni; A Facchini; C Capanni; C Stefanelli; B Tantini; C M Caldarera
Journal:  Biochem J       Date:  1999-07-15       Impact factor: 3.857

6.  Chemokine production by human chondrocytes.

Authors:  L Pulsatelli; P Dolzani; A Piacentini; T Silvestri; R Ruggeri; G Gualtieri; R Meliconi; A Facchini
Journal:  J Rheumatol       Date:  1999-09       Impact factor: 4.666

7.  IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain.

Authors:  H Sakurai; H Chiba; H Miyoshi; T Sugita; W Toriumi
Journal:  J Biol Chem       Date:  1999-10-22       Impact factor: 5.157

8.  Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo.

Authors:  J W Pierce; R Schoenleber; G Jesmok; J Best; S A Moore; T Collins; M E Gerritsen
Journal:  J Biol Chem       Date:  1997-08-22       Impact factor: 5.157

9.  Localisation of interleukin 8 in the synovial membrane, cartilage-pannus junction and chondrocytes in rheumatoid arthritis.

Authors:  B Deleuran; P Lemche; M Kristensen; C Q Chu; M Field; J Jensen; K Matsushima; K Stengaard-Pedersen
Journal:  Scand J Rheumatol       Date:  1994       Impact factor: 3.641

10.  Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes.

Authors:  M B Goldring; J R Birkhead; L F Suen; R Yamin; S Mizuno; J Glowacki; J L Arbiser; J F Apperley
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

View more
  7 in total

1.  Matrix metalloproteinase 13 loss associated with impaired extracellular matrix remodeling disrupts chondrocyte differentiation by concerted effects on multiple regulatory factors.

Authors:  Rosa Maria Borzí; Eleonora Olivotto; Stefania Pagani; Roberta Vitellozzi; Simona Neri; Michela Battistelli; Elisabetta Falcieri; Annalisa Facchini; Flavio Flamigni; Marianna Penzo; Daniela Platano; Spartaco Santi; Andrea Facchini; Kenneth B Marcu
Journal:  Arthritis Rheum       Date:  2010-08

2.  Sustained NF-kappaB activation produces a short-term cell proliferation block in conjunction with repressing effectors of cell cycle progression controlled by E2F or FoxM1.

Authors:  Marianna Penzo; Paul E Massa; Eleonora Olivotto; Francesca Bianchi; Rosa Maria Borzi; Adedayo Hanidu; Xiang Li; Jun Li; Kenneth B Marcu
Journal:  J Cell Physiol       Date:  2009-01       Impact factor: 6.384

3.  Differential requirements for IKKalpha and IKKbeta in the differentiation of primary human osteoarthritic chondrocytes.

Authors:  Eleonora Olivotto; Rosa Maria Borzi; Roberta Vitellozzi; Stefania Pagani; Annalisa Facchini; Michela Battistelli; Marianna Penzo; Xiang Li; Flavio Flamigni; Jun Li; Elisabetta Falcieri; Andrea Facchini; Kenneth B Marcu
Journal:  Arthritis Rheum       Date:  2008-01

4.  Simultaneous targeting of 5-LOX-COX and ODC block NNK-induced lung adenoma progression to adenocarcinoma in A/J mice.

Authors:  Gaurav Kumar; Jagan Mohan R Patlolla; Venkateshwar Madka; Altaf Mohammed; Qian Li; Yuting Zhang; Laura Biddick; Anil Singh; Allison Gillaspy; Stanley Lightfoot; Vernon E Steele; Levy Kopelovich; Chinthalapally V Rao
Journal:  Am J Cancer Res       Date:  2016-05-01       Impact factor: 6.166

5.  Biochemical and proteomic characterization of alkaptonuric chondrocytes.

Authors:  Daniela Braconi; Giulia Bernardini; Claretta Bianchini; Marcella Laschi; Lia Millucci; Loredana Amato; Laura Tinti; Tommaso Serchi; Federico Chellini; Adriano Spreafico; Annalisa Santucci
Journal:  J Cell Physiol       Date:  2012-09       Impact factor: 6.384

6.  Anemonin attenuates osteoarthritis progression through inhibiting the activation of IL-1β/NF-κB pathway.

Authors:  Zuqiang Wang; Junlan Huang; Siru Zhou; Fengtao Luo; Wei Xu; Quan Wang; Qiaoyan Tan; Liang Chen; Jun Wang; Hangang Chen; Lin Chen; Yangli Xie; Xiaolan Du
Journal:  J Cell Mol Med       Date:  2017-06-23       Impact factor: 5.310

7.  Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria.

Authors:  Adriano Spreafico; Lia Millucci; Lorenzo Ghezzi; Michela Geminiani; Daniela Braconi; Loredana Amato; Federico Chellini; Bruno Frediani; Elena Moretti; Giulia Collodel; Giulia Bernardini; Annalisa Santucci
Journal:  Rheumatology (Oxford)       Date:  2013-05-23       Impact factor: 7.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.